Status:
COMPLETED
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is designed to identify biomarkers which may predict improvement in progression free survival from treatment with Tarceva, in patients with advanced pancreatic cancer who failed one prior r...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- histologically or cytologically documented locally advanced-unresectable or metastatic pancreatic cancer;
- measurable disease according to RECIST;
- failure of at least one prior chemotherapy regimen, or who are deemed unsuitable for chemotherapy;
- ECOG performance status of 0-2.
Exclusion
- local or locally advanced-resectable pancreatic cancer;
- any other malignancies within last 5 years, except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer;
- major surgery within 2 weeks prior to randomization.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
207 Patients enrolled
Trial Details
Trial ID
NCT00674973
Start Date
June 1 2008
End Date
March 1 2015
Last Update
June 17 2016
Active Locations (71)
Enter a location and click search to find clinical trials sorted by distance.
1
Kogarah, New South Wales, Australia, 2217
2
St Leonards, New South Wales, Australia, 2065
3
Sydney, New South Wales, Australia, 2076
4
Box Hill, Victoria, Australia, 3128